Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital PIC

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Fineline Cube Aug 26, 2026
Company Deals

Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones

Fineline Cube Aug 26, 2026
Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug PIC

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

Fineline Cube Aug 26, 2026
Company Drug PIC

GSK’s Jemperli Wins FDA Priority Review for dMMR/MSI‑H Locally Advanced Rectal Cancer – PDUFA Date Set for February 2027

Fineline Cube Aug 26, 2026
Company Drug

Viatris Launches Ryzumvi in the US for Rapid Reversal of Pharmacologically-Induced Pupil Dilation

Fineline Cube Apr 2, 2024

Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market,...

Company Medical Device

Huihe Healthcare’s Vispearl Microsphere Earns Marketing Approval in China for Innovative Cancer Treatment

Fineline Cube Apr 2, 2024

Shanghai-based Huihe Healthcare, a developer of interventional medical devices for structural heart diseases, has secured...

Company Drug

J&J’s Nipocalimab Fast-Tracked by FDA for Reducing FNAIT Risk in Pregnant Adults

Fineline Cube Apr 2, 2024

The US Food and Drug Administration (FDA) has accepted Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Policy / Regulatory

US Lawmakers Expand Scrutiny on Chinese Biotech Firms with Potential Military Ties

Fineline Cube Apr 2, 2024

Despite his announced retirement from Congress effective April 19 this year, Mike Gallagher continues to...

Company

Lepu Biotechnology Reports 1,347% YOY Revenue Increase in 2023 Financial Results

Fineline Cube Apr 2, 2024

Lepu Biotechnology Co., Ltd (HKG: 2157), a biopharmaceutical company based in China, has released its...

Company Deals

Legend Biotech and Janssen Pharmaceutical Expand Partnership with Novartis for Carvykti Production

Fineline Cube Apr 2, 2024

Legend Biotech Corporation (NASDAQ: LEGN), a leading Chinese biotech firm, and its U.S. partner Janssen...

Company

Danaher Corporation Partners with Chongqing Liang Jiang New Area to Establish Western Innovation Center

Fineline Cube Apr 2, 2024

Danaher Corporation (NYSE: DHR), a leading science and technology services provider in the U.S., has...

Company Deals

China Medical System Expands Portfolio with Incyte’s Povorcitinib for Autoimmune Diseases

Fineline Cube Apr 2, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced a new cooperation and licensing agreement...

Company Drug

Shanghai Fosun Pharma and Meiji Seika Pharma Launch Phase III Studies for Anti-Infective Nacubactam

Fineline Cube Apr 2, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Medical Device

Johnson & Johnson MedTech Launches CPX4 PLUS Tissue Expander for Breast Reconstruction in China

Fineline Cube Apr 2, 2024

Johnson & Johnson (J&J, NYSE: JNJ) MedTech, a leading healthcare conglomerate in the US, has...

Company Deals

ETERN Therapeutics Secures Funding to Advance LLPS Platform and Clinical Trials for Anti-Tumor Drugs

Fineline Cube Apr 2, 2024

ETERN Therapeutics, a Shanghai-based developer of small-molecule anti-tumor drugs, has announced the commencement of a...

Company Drug

Junshi Biosciences Gets Green Light for Global Phase III Study of Tifcemalimab Combination Therapy in LS-SCLC

Fineline Cube Apr 2, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877), a leading biotech company based in China, has...

Policy / Regulatory

China’s National Joint Procurement Office Unveils Renewed Insulin Procurement Contracts

Fineline Cube Apr 1, 2024

The National Joint Procurement Office in China announced the upcoming renewal of drug procurement contracts...

Company Drug

FDA Reviews Eisai’s Monthly Maintenance Therapy for Early Alzheimer’s with Leqembi

Fineline Cube Apr 1, 2024

Last week, the US Food and Drug Administration (FDA) announced the acceptance of an indication...

Company Drug

Bristol Myers Squibb’s Krazati Trial Yields Positive Phase III Results in NSCLC

Fineline Cube Apr 1, 2024

Last week, Bristol Myers Squibb (BMS; NYSE: BMY) unveiled preliminary results from a Phase III...

Medical Device R&D

Chinese Scientists Discover Breakthrough Biodegradable Piezoelectric Material for Medical Implants

Fineline Cube Apr 1, 2024

A team of Chinese scientists from Southeast University in Nanjing has made significant strides in...

Company Drug Legal / IP R&D

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

Fineline Cube Apr 1, 2024

The China National Intellectual Property Administration (CNIPA) has upheld a key patent surrounding the CRISPR/Cas9...

Company Deals Policy / Regulatory

Shanghai Unveils Massive Investment Projects and Funds to Boost High-Tech Industries

Fineline Cube Apr 1, 2024

Shanghai has unleashed a flurry of policy-backed project signings and initiatives, marking a significant boost...

Company Drug

AstraZeneca’s AKT Inhibitor Truqap Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Apr 1, 2024

AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, has registered with Japan’s Ministry of Health,...

Company Drug

Kobayashi Pharmaceutical Faces Expanding Scandal Over Contaminated Red Yeast Rice Supplements

Fineline Cube Apr 1, 2024

Kobayashi Pharmaceutical, based in Japan, is facing a deepening scandal over contaminated red yeast rice...

Posts pagination

1 … 426 427 428 … 712

Recent updates

  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
  • Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth
  • Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China
  • EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk
  • Haisco Signs Exclusive Licensing Deal with Sentivera for Preclinical Autoimmune Asset – Up to USD 1.46 Billion in Milestones
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company PIC

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Company PIC

Fosun Pharma 2026H1 Revenue Rises 4.75% to RMB 20.44 Billion as Innovative Drugs and Globalization Power Growth

Company Deals Digital PIC

Takeda and Ant Group Form Digital Healthcare Partnership to Advance AI‑Driven Patient Care in China

Company Drug PIC

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.